Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Eli Lilly will work with RNA-focused Haya Therapeutics to search for new targets to develop drugs for metabolic conditions ...

BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Eli Lilly announced more positive results on its weekly insulin, called efsitora alfa, in type 2 diabetes patients. The ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

Pharmaceutical company Eli Lilly has announced a further €927 million investment at its facility at Raheen in Limerick, creating a further 150 jobs there.

The dark matter of long non-coding RNA (lncRNA) is shades brighter, after the signing of two major deals between biotech ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

(Reuters) -Wall Street was set for a higher open on Monday, rebounding from a week of heavy losses as investors remained ...